查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1992139

标靶治疗市场：按产品类型、给药途径和最终用户分類的全球市场预测 – 2026-2032 年

Targeted Therapy Market by Product Type, Route Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，标靶治疗市场价值将达到 724.1 亿美元，到 2026 年将成长至 773.5 亿美元，到 2032 年将达到 1,218 亿美元，复合年增长率为 7.71%。

主要市场统计数据
基准年 2025 724.1亿美元
预计年份：2026年 773.5亿美元
预测年份 2032 1218亿美元
复合年增长率 (%) 7.71%

为领导者提供关于标靶治疗不断发展的生态系统的简明概述，将科学突破与管理、监管和商业挑战联繫起来。

标靶治疗透过将分子层面的洞见与治疗方法设计相结合，正在重新定义临床医生和研发人员应对复杂疾病的方式。近年来，科学的进步推动了抗体药物复合体、单株抗体、蛋白水解物和小分子抑制剂等治疗方法从概念验证阶段迈向日益复杂的临床计画。因此，参与药物发现、开发和商业化的相关人员必须适应更快的迭代周期、更深入的生物标记整合以及更敏感的监管对话。本文概述了影响该领域发展的关键因素，并提出了短期战术性重点的预期。

科学创新与商业性创新的融合如何重塑标靶治疗整体情况中的治疗模式与营运重点。

近年来，标靶治疗发生了变革性转变，重塑了整体情况，加速了新治疗方法的研发，同时也带来了新的营运挑战。蛋白质工程和偶联化学技术的进步使抗体药物复合体（ADC）成为选择性递送细胞毒性物质的主要治疗方法。同时，单株抗体向全人源化和人源化结构的演进降低了免疫抗原性，从而延长了治疗疗程。此外，黏合剂和蛋白水解靶向嵌合体（PTC）等标靶蛋白降解技术的成熟，为调控以往难以攻克的标靶提供了新的途径，拓展了治疗选择。

分析 2025 年将公布的累积贸易和关税趋势及其对生物製药采购、生产和患者获取策略的连锁影响。

2025年即将实施的累积关税和贸易调整措施，为标靶治疗的整个价值链增添了新的复杂性，影响采购、生产和分销方面的决策。原料、特殊试剂和某些生物製药成分的关税变化增加了实际接收成本，促使采购团队重新评估供应商。这些压力通常会导致与契约製造的谈判週期延长，并促使企业重新关注双重采购策略，以维持临床和商业性的连续性。此外，关税带来的成本压力也影响新设施建设和技术投资的资金分配决策。

针对特定细分市场，结合产品模式、给药途径和最终用户交付考虑因素，可以製定开发优先顺序和商业化策略。

有效的细分能够明确治疗和商业回报的集中领域，有助于根据产品、给药途径和终端用户领域对产品组合进行优先排序。从产品类型来看，此领域可分为抗体药物复合体(ADC)、单株抗体、蛋白水解物和小分子抑制剂，每种产品都有其独特的开发、生产和商业化需求。在抗体药物复合体(ADC) 中，靶向 CD22 和 HER2 的药物在有效载荷选择和靶点结合策略方面存在差异，这会影响连接子的化学结构和细胞毒性有效载荷的选择。单株抗体分为嵌合体、全人源型和人源化型，每种类型都会影响免疫抗原性风险、给药频率和监管要求。蛋白水解物包括分子黏合剂和 PROTAC，它们在选择性光谱和临床前评估途径方面存在差异。另一方面，小分子抑制剂的范围很广，从 PARP 抑制剂到蛋白酶体抑制剂和蛋白酪氨酸激酶抑制剂，每一种都需要不同的药理特性和伴随诊断方法。

区域洞察重点介绍了美洲、欧洲、中东和非洲以及亚太地区的市场动态如何影响发展、进入和供应链策略。

区域趋势影响从临床开发策略到供应链配置和支付方合作等各方面，因此，地理洞察对于全球规划至关重要。儘管美洲的监管路径和支付体系各不相同，但该地区通常在创新治疗方法的早期应用和基于价值的合约试点计画中发挥主导作用。因此，製造商应优先考虑能够产生可靠临床证据并与支付方合作的框架，以证明其疗效和长期结果的可比较性。北美的生产能力和先进的临床试验基础设施支持复杂治疗方法的快速患者招募，但国内采购和关税因素可能会影响后期生产基地的选择。

产业领导者正在投资策略性企业活动和能力建设，以将技术创新转化为具有临床意义的治疗方法和永续的商业性优势。

产业领导企业正在实施一系列策略措施，以最大限度地发挥标靶治疗的潜力，同时应对相关的科学和商业性复杂性。许多机构正在加速投资于标准化偶联技术、抗体工程和降解化学的平台，以降低技术风险并缩短临床试验时间。另一些机构则与生技公司、学术机构和合约开发组织 (CDO) 建立合作关係，以利用专家能力，而无需承担全部内部开发成本。这些伙伴关係模式支持灵活的产能扩展，并能够快速回应每种治疗方法不断变化的需求。

为标靶治疗的领导者提供切实可行的跨部门建议，以协调生物标记主导的开发、具有韧性的供应链和以患者为中心的商业化。

致力于最大化标靶治疗价值的领导者应采取务实且跨领域的措施，将科学优先事项与商业性现实和供应链韧性相结合。首先，在临床开发早期阶段整合生物标记策略和卫生经济学，以确保试验能够产生支付方所需的证据。协调这些功能可以减少后期延误，并强化价值主张。其次，透过认证区域契约製造合作伙伴并设计能够实现关键组件互换性的平台，实现采购和生产多元化。这可以降低关税衝击和短期供应中断带来的风险。

透明的混合方法研究框架，结合相关人员访谈、临床和专利分析、供应链映射和基于情境的检验，确保了可靠的见解。

本研究整合了定性和定量方法，结合与关键相关人员的对话、系统的二手资料研究和技术综述，从而对标靶治疗趋势有了更深入的了解。主要研究包括对临床研究人员、监管专家、生产负责人、支付方和分销专家的深入访谈，揭示了实际操作中的限制因素和新兴的最佳实践。透过这些对话进行主题编码，识别出反覆出现的营运挑战，例如低温运输脆弱性、监管差异以及支付方要求的证据要求。

对科学进步、供应链考量和支付方期望如何决定标靶治疗的成功与否进行全面分析和策略性展望。

总之，标靶治疗领域正处于科学创新、营运复杂性和商业性审查交会的十字路口。抗体药物复合体、单株抗体、蛋白水解剂和小分子抑制剂的进步拓展了研发人员可用的工具箱，但要实现治疗和商业预期，需要研发、生产、监管和支付方等各部门的协调努力。贸易和关税波动带来了新的营运挑战，迫使企业制定更详细的供应链计画和策略采购决策；同时，监管和报销框架的区域差异也要求企业采取个人化的市场准入策略。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章标靶治疗市场：依产品类型划分

  • 抗体药物复合体
    • CD22标靶
    • HER2靶点
  • 单株抗体
    • 嵌合体
    • 完全人形
    • 人性化
  • 蛋白质降解剂
    • 分子黏合剂
    • PROTAC
  • 小分子抑制剂
    • PARP抑制剂
    • 蛋白酶体抑制剂
    • 蛋白酪氨酸激酶抑制剂

第九章标靶治疗市场：依给药途径划分

  • 静脉
  • 口服
  • 皮下

第十章标靶治疗市场：依最终用户划分

  • 居家医疗
  • 医院药房
  • 零售药房
  • 专科诊所

第十一章标靶治疗市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章标靶治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章标靶治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章：美国标靶治疗市场

第十五章：中国标靶治疗市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc.
  • Bristol Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche AG
  • Genmab A/S
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-CA7E340319CF

The Targeted Therapy Market was valued at USD 72.41 billion in 2025 and is projected to grow to USD 77.35 billion in 2026, with a CAGR of 7.71%, reaching USD 121.80 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 72.41 billion
Estimated Year [2026] USD 77.35 billion
Forecast Year [2032] USD 121.80 billion
CAGR (%) 7.71%

A concise orientation to the evolving targeted therapy ecosystem that connects scientific breakthroughs with operational, regulatory, and commercial imperatives for leaders

Targeted therapies are redefining how clinicians and developers approach complex diseases by aligning molecular insights with therapeutic design. Recent scientific advances have pushed modalities such as antibody drug conjugates, monoclonal antibodies, protein degraders, and small molecule inhibitors from proof-of-concept into increasingly sophisticated clinical programs. As a result, stakeholders across discovery, development, and commercialization must adapt to faster iteration cycles, deeper biomarker integration, and more nuanced regulatory dialogues. This introduction frames the critical forces shaping the field and sets expectations for near-term tactical priorities.

Investors and R&D leaders now judge programs not only on biological rationale but also on manufacturability, supply chain robustness, and reimbursement pathways. Clinical teams emphasize patient selection and companion diagnostics to improve trial efficiency and therapeutic impact, while manufacturing groups prioritize platform consistency and scalable processes to reduce variability. In parallel, payers and health systems increasingly demand real-world evidence and outcomes-based contracting to justify premium pricing for novel modalities. These converging pressures create both friction and opportunity: organizations that align scientific excellence with operational execution will capture disproportionate value.

Transitioning from early discovery to widespread adoption requires deliberate alignment across cross-functional teams. This report begins by outlining transformational shifts in science and market structure, then explores regulatory and trade headwinds, segment-level implications, regional dynamics, and strategic recommendations intended to inform immediate actions and longer-term planning.

How converging scientific, regulatory, and commercial innovations are reshaping therapeutic modalities and operational priorities across the targeted therapy landscape

The last several years have produced transformative shifts that are remapping the targeted therapy landscape, accelerating novel modalities while raising new operational imperatives. Technological advances in protein engineering and conjugation chemistry have elevated antibody drug conjugates into a leading modality for delivering cytotoxic payloads selectively, while monoclonal antibody evolution toward fully human and humanized constructs has reduced immunogenicity and enabled longer treatment windows. Simultaneously, the maturation of targeted protein degradation-through molecular glues and proteolysis targeting chimeras-introduces routes to modulate previously intractable targets, broadening the therapeutic opportunity set.

These scientific gains intersect with innovations in small molecule design, where tailored inhibitors such as PARP, proteasome, and tyrosine kinase agents offer complementary mechanisms for multi-modal regimens. At the same time, digital tools and artificial intelligence accelerate lead identification and predictive modeling, shortening development cycles and improving candidate selection. Regulatory frameworks are adapting to these modalities by offering more targeted guidance on combination approaches, biomarker-driven approvals, and adaptive trial designs, yet variability in regional expectations is prompting sponsors to design programs with parallel regulatory engagement.

Commercially, payers and providers are demanding clearer evidence of comparative effectiveness and value-based pricing models, which drives closer alignment between clinical development and health economics planning. Manufacturing and cold-chain logistics improvements are enabling new route-of-administration strategies, particularly increased attention to subcutaneous and home-administered formulations that improve patient convenience and lower system costs. The net effect is a landscape where innovation is rapid, but success increasingly depends on integrated scientific, regulatory, and commercial execution.

Analyzing the cumulative trade and tariff dynamics announced for 2025 and their cascading effects on biopharmaceutical sourcing, manufacturing, and patient access strategies

The introduction of cumulative tariffs and trade adjustments announced for 2025 has introduced a new layer of complexity across the targeted therapy value chain, affecting sourcing, manufacturing, and distribution decisions. Tariff changes on raw materials, specialized reagents, and certain biologics-related components increase effective landed costs and prompt procurement teams to reassess supplier footprints. These pressures often translate into longer negotiation cycles with contract manufacturers and a renewed emphasis on dual-sourcing strategies to maintain clinical and commercial continuity. Moreover, tariff-driven cost pressures influence capital allocation decisions for new facility builds and technology investments.

Manufacturers facing increased import duties for key inputs have adopted several mitigation strategies, including reshoring select production steps closer to end markets, qualifying local suppliers where possible, and redesigning supply chains to reduce reliance on tariff-exposed nodes. Regulatory harmonization efforts and free trade agreements remain uneven, so companies must navigate a patchwork of customs procedures and compliance requirements that can delay batch release and increase lead times. For programs reliant on time-sensitive biologics or cold-chain logistics, even modest tariff-related delays can disrupt clinical trial timelines and product launches, which in turn impacts forecasting and inventory policies at distributors and hospitals.

In response, senior leaders are recalibrating vendor contracts to include tariff pass-through clauses and investing in supply chain transparency tools to model exposure across scenarios. Strategic sourcing now requires closer collaboration between commercial, regulatory, and procurement teams to optimize total landed cost while preserving product integrity and patient access. The cumulative effect of these trade measures is to accelerate existing trends toward regionalization of production and enhanced supply chain resilience, with implications for pricing strategies, partner selection, and manufacturing footprint optimization.

Segment-focused insights that integrate product modality, administration route, and end-user delivery considerations to inform development prioritization and commercialization tactics

Effective segmentation clarifies where therapeutic and commercial returns will concentrate and informs portfolio prioritization across product, administration route, and end-user domains. When viewed through product type, the landscape differentiates antibody drug conjugates, monoclonal antibodies, protein degraders, and small molecule inhibitors, each with distinct development, manufacturing, and commercialization demands. Within antibody drug conjugates, agents directed at CD22 and HER2 represent divergent payload selection and target engagement strategies that influence linker chemistry and cytotoxic payload choices. Monoclonal antibodies subdivide into chimeric, fully human, and humanized formats, affecting immunogenicity risk, dosing frequency, and regulatory expectations. Protein degraders encompass molecular glues and PROTACs, which differ in selectivity profiles and preclinical assessment pathways, while small molecule inhibitors range from PARP inhibitors to proteasome and tyrosine kinase inhibitors, each requiring different pharmacology and companion diagnostic approaches.

Routes of administration add another layer of strategic differentiation, spanning intravenous, oral, and subcutaneous delivery. Intravenous therapies often necessitate hospital-based administration and complex cold-chain logistics, while oral agents increase outpatient convenience and adherence considerations. Subcutaneous formulations are gaining prominence as a patient-friendly alternative that can reduce infusion center burden and enable home-based care models. End-user segmentation further refines go-to-market and support needs, with home care, hospital pharmacy, retail pharmacy, and specialty clinics each presenting unique distribution, reimbursement, and patient support requirements. Home care models require robust patient education and remote monitoring, hospital pharmacy environments demand streamlined formulary access and inpatient logistics, retail pharmacies offer broad outpatient reach but require clear dispensing pathways, and specialty clinics provide concentrated clinical expertise and can facilitate complex care pathways.

Understanding the intersection across these dimensions enables sponsors to tailor development and commercialization tactics, align clinical trial designs with likely real-world administration settings, and structure stakeholder engagement plans that reflect where and how therapies will be delivered and reimbursed.

Regional intelligence spotlighting how Americas, Europe Middle East & Africa, and Asia-Pacific market dynamics influence development, access, and supply chain strategies

Regional dynamics shape everything from clinical development strategies to supply chain configuration and payer interactions, making geographic insight indispensable for global planning. In the Americas, regulatory pathways and payer systems are highly varied, but the region often leads in early adoption of innovative therapies and value-based contracting pilots; manufacturers should therefore prioritize robust clinical evidence generation and payer engagement frameworks that demonstrate comparative effectiveness and long-term outcomes. North American manufacturing capacity and advanced clinical trial infrastructure support rapid enrollment for complex modalities, but domestic sourcing and tariff considerations can influence where late-stage production is sited.

Europe, Middle East & Africa present a mosaic of regulatory expectations and reimbursement mechanisms that require tailored market entry strategies. European health technology assessment bodies frequently demand rigorous health economic data and may negotiate centralized procurement for high-cost therapies, while reimbursement timelines can vary substantially between markets. The Middle East and Africa offer pockets of high unmet need and concentrated procurement initiatives, yet accessibility and local regulatory capacity vary widely, prompting sponsors to adopt differentiated commercial models and targeted access programs.

Asia-Pacific continues to expand clinical development capacity and local manufacturing capabilities, with several markets emphasizing domestic innovation and regulatory modernization. Countries across the region are increasingly receptive to data generated from local patient populations and are investing in infrastructure that supports large-scale oncology and specialty care trials. Pricing and reimbursement policies differ markedly between public and private systems, so sponsors should design regional strategies that balance localized evidence generation with efficient regulatory pathways. Across regions, the convergence of digital health adoption and decentralized trial methodologies presents opportunities to harmonize patient recruitment, monitoring, and long-term outcomes collection at scale.

Strategic corporate moves and capability investments industry leaders are deploying to convert modality innovation into clinically meaningful therapies and sustainable commercial advantage

Industry leaders are deploying a range of strategic moves to capture the promise of targeted therapies while managing the attendant scientific and commercial complexity. Many organizations are accelerating platform investments that standardize conjugation technologies, antibody engineering, and degradation chemistries to reduce technical risk and shorten time to clinic. Others are forging collaborations across biotech partners, academic centers, and contract development organizations to access specialized capabilities without assuming the full cost of in-house development. These partnership models support flexible capacity scaling and enable rapid response as modality-specific demand shifts.

Commercial strategies now emphasize integrated launch planning that brings clinical development, regulatory engagement, health economics, and market access teams together earlier in the lifecycle. Leaders invest in real-world evidence generation and outcomes tracking to demonstrate value to payers and providers, and they deploy patient support services to promote adherence and optimize clinical outcomes. On the manufacturing front, companies are diversifying supplier bases, qualifying secondary manufacturing sites, and expanding fill-finish capabilities to mitigate supply disruption risks.

Pipeline management has become more selective, with sponsors prioritizing indications and combinations that maximize therapeutic differentiation and align with feasible reimbursement pathways. Talent strategies focus on hiring scientists and executives with cross-functional experience in biologics, regulatory affairs, and commercial operations. The net effect is a more disciplined, partnership-driven, and execution-focused industry posture that seeks to translate scientific promise into durable therapeutic and commercial success.

Actionable cross-functional recommendations to align biomarker-driven development, resilient supply chains, and patient-centric commercialization for leaders in targeted therapy

Leaders seeking to maximize value in targeted therapy should adopt a set of actionable, cross-functional measures that align scientific priorities with commercial realities and supply chain resilience. First, integrate biomarker strategy and health economics early in clinical development to ensure trials generate the evidence payers require; connecting these functions reduces later-stage delays and strengthens value narratives. Second, diversify sourcing and manufacturing by qualifying regional contract manufacturing partners and by designing platforms that permit interchangeability of critical components; this reduces exposure to tariff shocks and short-term supply interruptions.

Third, prioritize patient-centric administration strategies by investing in subcutaneous formulation development and patient support infrastructure that enable home-based care where clinically appropriate. Fourth, pursue strategic collaborations to access specialized modalities such as molecular glues or PROTAC chemistry while preserving optionality through staged investment and clear milestone gating. Fifth, engage proactively with regulatory authorities across key jurisdictions to align on adaptive trial designs and biomarker-driven approval pathways, reducing the risk of divergent requirements and costly trial amendments.

Finally, operationalize data and analytics to monitor supply chain exposure, clinical trial progress, and real-world outcomes in near real time; these capabilities enable faster course corrections and more informed commercial rollouts. Collectively, these actions help organizations navigate complexity, preserve optionality, and accelerate the translation of scientific advances into patient benefit and sustained commercial performance.

A transparent mixed-methods research framework combining stakeholder interviews, clinical and patent analysis, supply chain mapping, and scenario-based validation to ensure robust insights

This research synthesizes qualitative and quantitative approaches to produce a nuanced view of targeted therapy dynamics, combining primary stakeholder engagement with structured secondary analysis and technical review. Primary research included in-depth interviews with clinical investigators, regulatory specialists, manufacturing leaders, payers, and distribution experts to surface practical constraints and emerging best practices. These dialogues informed thematic coding and identified recurring operational pain points such as cold-chain vulnerability, regulatory heterogeneity, and payer evidence expectations.

Secondary analysis encompassed peer-reviewed literature, clinical trial registries, patent filings, and publicly available regulatory guidance to validate scientific trends and modality-specific technical requirements. Supply chain mapping leveraged public customs data and industry logistics reporting to trace typical component flows and identify tariff-sensitive nodes. Additionally, product development case studies and manufacturing due diligence informed assessments of platform readiness and scale-up risk.

Analytical methods included cross-sectional synthesis to compare modality characteristics, scenario modeling to evaluate tariff and supply disruption impacts, and triangulation across data sources to ensure robustness. Wherever possible, findings were stress-tested against recent regulatory decisions, clinical readouts, and announced capacity investments to ensure recommendations reflect operational realities. This mixed-methods approach offers a replicable framework for translating scientific advances into strategic priorities while acknowledging uncertainty and preserving managerial flexibility.

Synthesis and strategic outlook summarizing how scientific advances, supply chain considerations, and payer expectations will determine success in targeted therapy

In closing, the targeted therapy field stands at an inflection point where scientific ingenuity meets operational complexity and commercial scrutiny. Advances across antibody drug conjugates, monoclonal antibodies, protein degraders, and small molecule inhibitors have expanded the toolkit available to developers, but realizing therapeutic and commercial promise requires coordinated action across development, manufacturing, regulatory, and payer engagement functions. Trade and tariff changes add a new operational layer that compels more granular supply chain planning and strategic sourcing decisions, while regional heterogeneity in regulatory and reimbursement frameworks necessitates tailored go-to-market approaches.

Organizations that invest early in integrated evidence generation, diversify manufacturing footprints, and design patient-centered administration strategies will improve their odds of successful adoption. Partnerships remain a powerful mechanism to access specialized capabilities and to share risk, and leaders who combine platform investments with selective external collaborations are best positioned to scale efficiently. Ultimately, targeted therapies will continue to reshape treatment paradigms, but success will hinge on the ability to translate molecular innovation into reproducible clinical outcomes, reliable supply, and validated value to payers and providers.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Targeted Therapy Market, by Product Type

  • 8.1. Antibody Drug Conjugates
    • 8.1.1. Cd22 Directed
    • 8.1.2. Her2 Directed
  • 8.2. Monoclonal Antibodies
    • 8.2.1. Chimeric
    • 8.2.2. Fully Human
    • 8.2.3. Humanized
  • 8.3. Protein Degraders
    • 8.3.1. Molecular Glues
    • 8.3.2. Protacs
  • 8.4. Small Molecule Inhibitors
    • 8.4.1. Parp Inhibitors
    • 8.4.2. Proteasome Inhibitors
    • 8.4.3. Tyrosine Kinase Inhibitors

9. Targeted Therapy Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Targeted Therapy Market, by End User

  • 10.1. Home Care
  • 10.2. Hospital Pharmacy
  • 10.3. Retail Pharmacy
  • 10.4. Specialty Clinic

11. Targeted Therapy Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Targeted Therapy Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Targeted Therapy Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Targeted Therapy Market

15. China Targeted Therapy Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. AbbVie Inc.
  • 16.6. Amgen Inc.
  • 16.7. Astellas Pharma Inc.
  • 16.8. AstraZeneca PLC
  • 16.9. Bayer AG
  • 16.10. BeiGene, Ltd.
  • 16.11. Biogen Inc.
  • 16.12. BioMarin Pharmaceutical Inc.
  • 16.13. Bristol Myers Squibb Company
  • 16.14. Eisai Co., Ltd.
  • 16.15. Eli Lilly and Company
  • 16.16. Exelixis, Inc.
  • 16.17. F. Hoffmann-La Roche AG
  • 16.18. Genmab A/S
  • 16.19. Gilead Sciences, Inc.
  • 16.20. GlaxoSmithKline plc
  • 16.21. Incyte Corporation
  • 16.22. Johnson & Johnson Services, Inc.
  • 16.23. Merck & Co., Inc.
  • 16.24. Merck KGaA
  • 16.25. Novartis AG
  • 16.26. Pfizer Inc.
  • 16.27. Regeneron Pharmaceuticals, Inc.
  • 16.28. Sanofi S.A.
  • 16.29. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL TARGETED THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TARGETED THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TARGETED THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TARGETED THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES TARGETED THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA TARGETED THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TARGETED THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TARGETED THERAPY MARKET SIZE, BY CD22 DIRECTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TARGETED THERAPY MARKET SIZE, BY CD22 DIRECTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TARGETED THERAPY MARKET SIZE, BY CD22 DIRECTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TARGETED THERAPY MARKET SIZE, BY HER2 DIRECTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TARGETED THERAPY MARKET SIZE, BY HER2 DIRECTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TARGETED THERAPY MARKET SIZE, BY HER2 DIRECTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TARGETED THERAPY MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TARGETED THERAPY MARKET SIZE, BY CHIMERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TARGETED THERAPY MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TARGETED THERAPY MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TARGETED THERAPY MARKET SIZE, BY FULLY HUMAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TARGETED THERAPY MARKET SIZE, BY FULLY HUMAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TARGETED THERAPY MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TARGETED THERAPY MARKET SIZE, BY HUMANIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TARGETED THERAPY MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TARGETED THERAPY MARKET SIZE, BY MOLECULAR GLUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TARGETED THERAPY MARKET SIZE, BY MOLECULAR GLUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TARGETED THERAPY MARKET SIZE, BY MOLECULAR GLUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTACS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTACS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTACS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TARGETED THERAPY MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TARGETED THERAPY MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TARGETED THERAPY MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TARGETED THERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TARGETED THERAPY MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TARGETED THERAPY MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TARGETED THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TARGETED THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TARGETED THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS TARGETED THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GCC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 149. GCC TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 150. GCC TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 151. GCC TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 152. GCC TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. GCC TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. G7 TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. G7 TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 173. G7 TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 174. G7 TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 175. G7 TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 176. G7 TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. G7 TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. NATO TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. NATO TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 181. NATO TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 182. NATO TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 183. NATO TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 184. NATO TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. NATO TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES TARGETED THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA TARGETED THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)